AAV Vectors Vaccines Against Infectious Diseases. - Wikidata - awgldk - TriplyDB

AAV Vectors Vaccines Against Infectious Diseases.

AAV Vectors Vaccines Against Infectious Diseases.

http://www.wikidata.org/entity/Q37498000

about

Proof of concept study with an HER-2 mimotope anticancer vaccine deduced from a novel AAV-mimotope library platform Viral vector-based influenza vaccines.Virus-vectored influenza virus vaccines.A Novel Adeno-Associated Virus-Based Genetic Vaccine Encoding the Hepatitis C Virus NS3/4 Protein Exhibits Immunogenic Properties in Mice Superior to Those of an NS3-Protein-Based Vaccine.The SUMOylation Pathway Restricts Gene Transduction by Adeno-Associated Viruses Reprogramming Immune Response With Capsid-Optimized AAV6 Vectors for Immunotherapy of Cancer Large-scale adenovirus and poxvirus-vectored vaccine manufacturing to enable clinical trials.A Lentiviral Vector Allowing Physiologically Regulated Membrane-anchored and Secreted Antibody Expression Depending on B-cell Maturation Status.Vectored immunoprophylaxis: an emerging adjunct to traditional vaccination.Intradermal Immunization with rAAV1 Vector Induces Robust Memory CD8(+) T Cell Responses Independently of Transgene Expression in DCs.Adeno-Associated Viral Vectors at the Frontier between Tolerance and Immunity.One shot forward for HIV prevention.

P2860

Q28596492-1C7E4C9E-E330-4D1E-B7B4-A5D581117F1F Q30390938-41F726C6-8157-4ED7-834A-59EDC59D3CF3 Q34102268-8226B423-F699-4CC6-8354-57CD7FD15CAC Q35837765-32B61982-E0B5-4BD6-9D39-47BAF7AB2979 Q35857358-E8AB2615-3DAD-47C9-A617-32E5106DB546 Q35949356-5E1890C3-F662-46BB-AA41-9CA4C0FAAEA5 Q38443390-B8F5D6F6-FC55-4847-8344-469F9A5F4A1A Q38843133-8CA7817E-1E48-4D14-9B8D-D15DCBC23C20 Q40040079-88615BB0-1EDF-4958-A2DE-E4FF2C855FB6 Q40117829-A5E45638-0BFA-4089-8011-F278DC044BB7 Q42150059-80057F31-F596-44BA-95B2-67B98982FF65 Q51847620-B694F8F8-D3AF-4D24-ACB2-50BDDA9D950D

P2860

AAV Vectors Vaccines Against Infectious Diseases.

http://www.wikidata.org/entity/Q37498000

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 21 January 2014

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

AAV Vectors Vaccines Against Infectious Diseases.

@en

AAV Vectors Vaccines Against Infectious Diseases.

@nl

type

label

AAV Vectors Vaccines Against Infectious Diseases.

@en

AAV Vectors Vaccines Against Infectious Diseases.

@nl

prefLabel

AAV Vectors Vaccines Against Infectious Diseases.

@en

AAV Vectors Vaccines Against Infectious Diseases.

@nl

P1433

Q37498000-9A7A25C3-B30F-41A8-BC17-3DF1BB62B3DC

P1476

Q37498000-B77D2BEB-5FC0-4E56-8334-A7B80C4E6B9E

P2093

Q37498000-7E3F09AF-DFBF-41D1-8BCB-CBF276ABC5B9

P2860

Q37498000-01BA8307-B83A-4776-8CD6-B0D8F0B0DF3B

Q37498000-077137F1-583D-485A-8B1B-D0D56B77ED50

Q37498000-0D4CF7A0-90AC-4610-BEE2-59236ED1A564

Q37498000-122CA337-35EB-4DFC-B899-6A9B0BD904F4

Q37498000-13F3DDF8-E9EF-441C-A6DD-782CA09B7EE6

Q37498000-15FB6748-E8F1-4301-85FA-839039BF4098

Q37498000-194F1DDC-49DC-4198-93AC-6DB5C409F669

Q37498000-204F26C1-2225-4982-B83A-0690104412F4

Q37498000-210616E6-0A2B-49F2-AD12-F0C211DF5C23

Q37498000-2C9ED9B8-9214-4A88-9178-E7FAEB547167

P304

Q37498000-7F939CB9-A5E6-4DF3-81D8-C87A1AA901A9

P31

Q37498000-9F6421CA-9FBF-4443-8400-A8F9516A4540

P356

Q37498000-57817109-0422-4DA1-97E0-0A310957F874

P478

Q37498000-AADF09BC-C4F0-4772-8BC1-153EF852A8B9

P50

Q37498000-3A8B47B7-8095-46C6-9CCD-6EF7FC06363D

P577

Q37498000-1928CFBC-00ED-4BAD-93FD-B9E07ABE14A2

P5875

Q37498000-ECE8B43A-A7E1-4AD9-BD2A-A5885904EA0D

P698

Q37498000-3E03302C-1686-4D01-B083-A88C517C8322

P921

Q37498000-82813B7A-7414-47AE-9FA7-3D90D24BDDE0

P932

Q37498000-792E64DC-7FF1-4CC1-B6B4-407ED84D1DFF

P356

FIMMU.2014.00005

P1433

Frontiers in Immunology

P1476

AAV Vectors Vaccines Against Infectious Diseases

@en

P2093

Karen Nieto

http://www.w3.org/2001/XMLSchema#string

P2860

Development of AAVLP(HPV16/31L2) particles as broadly protective HPV vaccine candidate

The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy.

A recombinant Hendra virus G glycoprotein-based subunit vaccine protects ferrets from lethal Hendra virus challenge

Self-complementary AAVs induce more potent transgene product-specific immune responses compared to a single-stranded genome

Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial

Vaccine protection against lethal homologous and heterologous challenge using recombinant AAV vectors expressing codon-optimized genes from pandemic swine origin influenza virus (SOIV).

Intranasal antibody gene transfer in mice and ferrets elicits broad protection against pandemic influenza.

Optimization of stealth adeno-associated virus vectors by randomization of immunogenic epitopes.

Hendra and Nipah viruses: different and dangerous.

Adeno-associated virus serotypes: vector toolkit for human gene therapy.

P304

5

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3389/FIMMU.2014.00005

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-01-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

259986637

http://www.w3.org/2001/XMLSchema#string

P698

24478774

http://www.w3.org/2001/XMLSchema#string

P921

vector-borne disease

P932

3896988

http://www.w3.org/2001/XMLSchema#string